Yahoo Home 
Anjalee Khemlani is an award-winning healthcare and business reporter at Yahoo Finance covering the entire healthcare sector, including pharma, health tech, providers, insurers, PBMs and health equity. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio, and has been a guest on global broadcast and radio stations covering the Covid-19 pandemic and global public health.
Yahoo FinanceWeight-loss drug competition heats up with growing pill market
GLP-1 pills are the next frontier for the weight-loss market.
- Yahoo Finance
Why Big Pharma is betting on telehealth strategies
The telehealth world is entering a new phase of vertical integration in healthcare.
- Yahoo Finance
Eli Lilly slashes Zepbound prices for self-pay patients
Eli Lilly is trying to reduce shortages of its Zepbound weight loss GLP-1 by launching vials and lowering prices for out-of-pocket payers.
- Yahoo Finance
Pfizer, joining Lilly, enters the direct-to-consumer market with a telehealth and prescription platform
Pfizer is launching a new direct-to-consumer platform that it hopes will help patients get access to medicines faster.
- Yahoo Finance
Medicare Advantage could lead to lower hospital credit ratings: S&P
Medicare has notoriously underpaid hospitals. Private insurers offering Medicare Advantage are even worse, as their delay and denial tactics squeeze hospital margins further.
- Yahoo Finance
GLP-1s partly to blame for spike in health insurance costs in 2025
GLP-1 use is adding to employer health costs and making it more expensive for employees as well — regardless of whether an employee is on the drug or not.
- Yahoo Finance
Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.
Medicare drug pricing has been a concern for drugmakers for the past year, as they negotiated with the government. The investor impact appears to be muted, as Wall Street has not reacted in the hours since the reveal. Others? That's a different story.
- Yahoo Finance
Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations
CMS has finally revealed its first set of negotiated prices for 10 prescription drugs that will lower the government's spend on Part D drugs for seniors starting in 2026.
- Yahoo Finance
Oscar Health CEO: Why the company is a 'healthcare pi?ata' in an election year
Oscar Health is facing ongoing uncertainty in light of the upcoming presidential election, but it is also diversifying to stay on track for what could be its first profitable year.
- Yahoo Finance
What Eli Lilly, Novo Nordisk earnings reveal about the future of GLP-1 sales
GLP-1s continue to fuel investor interest in market competition, as companies prepare to differentiate themselves in the coming year.
- Yahoo Finance
Eli Lilly stock jumps on GLP-1 sales, end of manufacturing shortage
Eli Lilly's blowout quarter driven by GLP-1s signals end of manufacturing constraints.
- Yahoo Finance
Novo Nordisk CFO says Wegovy sales miss a 'blip'
Novo Nordisk reported a softer-than-expected quarter, which CFO Karsten Knudsen told Yahoo Finance is just a blip.
- Yahoo Finance
Who's to blame as Moderna's stock falls amid slashed guidance?
Moderna slashed its sales guidance on lower-than-expected demand in Europe. CEO Stéphane Bancel tells Yahoo Finance why.
- Yahoo Finance
Wall Street is still jittery on GLP-1s
Wall Street has taken medical devices, as well as other sectors, on a roller-coaster ride in the past year in anticipation of an outsized impact from GLP-1s, which has yet to materialize.
- Yahoo Finance
Why Wall Street is unfazed by Medicare drug pricing threat
Medicare drug pricing negotiations are done and Wall Street is getting a good signal from drug CEOs.
- Yahoo Finance
AstraZeneca CEO: We're building '2 supply chains' to avoid impact of US-China tensions
AstraZeneca is building out manufacturing capacity to manage turbulent geopolitical times.
- Yahoo Finance
GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar
GoodRx announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira Thursday, adding to an increasingly competitive market.
- Yahoo Finance
UnitedHealth was too 'optimistic, in hindsight' about the impact of Change Healthcare cyberattack: CEO
UnitedHealth Group overestimated the impact of a hack. But it has also seen cost savings with more technology use across its business divisions.
- Yahoo Finance
FTC Chair Khan slams PBMs for higher drug prices in an interim report on the industry
The FTC released a much-anticipated interim report without taking any action. It comes as the Biden administration prepares for an uncertain election outcome.
- Yahoo Finance
Eli Lilly awaits head-to-head study on GLP-1s after new report reaffirms superiority
A new study looked at patient data and concluded Eli Lilly's GLP-1 drugs fare better for weight loss than Novo Nordisk's Ozempic.